WPD Pharmaceuticals - daher weht der Wind!
Seite 52 von 54 Neuester Beitrag: 30.09.21 10:06 | ||||
Eröffnet am: | 30.01.20 12:18 | von: moneywork4. | Anzahl Beiträge: | 2.338 |
Neuester Beitrag: | 30.09.21 10:06 | von: tom.tom | Leser gesamt: | 375.131 |
Forum: | Hot-Stocks | Leser heute: | 101 | |
Bewertet mit: | ||||
Seite: < 1 | ... | 48 | 49 | 50 | 51 | | 53 | 54 > |
Moderation
Zeitpunkt: 30.06.21 11:26
Aktion: Löschung des Beitrages
Kommentar: Regelverstoß - Unbelegte Aussage.
Zeitpunkt: 30.06.21 11:26
Aktion: Löschung des Beitrages
Kommentar: Regelverstoß - Unbelegte Aussage.
Bleiben Sie
Designation permits company to frequent interactions with FDA
Berubicin is used for the management of patients with recurring glioblastoma multiforme (GBM). As previously reported, CNS had also received Orphan Drug Designation from the FDA for Berubicin to manage patients with recurring GBM.
The Fast Track Designation permits more recurrent communications with the FDA to accelerate the expansion and appraisal procedure for drugs envisioned to treat severe or life-threatening disorders and validate the possibility of tackling unmet medical requirements.
Getting Fast Track Designation from the U.S. FDA is considerable attainment in the progression of Berubicin for the management of glioblastoma, the most belligerent, lethal, and treatment-resistant type of cancer that customs in the brain. Many patients have almost no expressive opportunities, and thousands lose the fight against this cancer every year. With this description, CNS now has an enhanced pathway to endorsing Berubicin and a clear opening to bring this hypothetically impactful untried treatment more advantageously.
CNS recently announced the beginning of patient registration in its revision of Berubicin to manage recurring glioblastoma multiforme. WPD would meaningfully profit from the progression of Berubicin as an action for GBM as it has the privileges to produce and trade the drug applicant in 29 nations.
WPD Pharmaceuticals to borrow up to $150,000
WPD Pharmaceuticals sp. z.o.o. its Polish subsidiary has agreed to derive up to $150,000 from both companies, each organized by insiders. The advances bear interest at 10% per annum and ripe on April 2, 2022. The advances are not translatable to stocks. Therefore, the insider advances are exempted from the estimate and minority stockholder consent necessities.
Medulloblastoma is a cancerous brain tumor that starts in the lower back part of the brain, called the cerebellum. Medulloblastoma accounts for nearly 10% of all childhood brain tumors. These tumors occur exclusively in the posterior fossa and have the potential for leptomeningeal spread. Signs and symptoms of medulloblastoma may include headaches, nausea, vomiting, tiredness, dizziness, double vision, poor coordination and unsteady walk. Medulloblastoma is diagnosed based upon thorough clinical and neurological evaluation, detection of characteristic symptoms and physical findings, patient history, and specialized diagnostic tests.
DelveInsight’s, “Medulloblastoma Pipeline Insight, 2021,” report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Medulloblastoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Request for free sample report: https://www.delveinsight.com/sample-request/...stoma-pipeline-insight
Some of Medulloblastoma Companies are:
Oncurious
Y-mAbs Therapeutics
Senhwa Biosciences
Sun Pharmaceutical Industries
Roche
Nelum
WPD Pharmaceuticals
Midatech
Kintara Therapeutics
VBI Vaccines
Oncoheroes Biosciences
And Many Others